57. Weinshenker BG, O’Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878–886
58. Papeix C, Deseze J, Pierrot-Deseilligny C, et al. French therapeutic experience of Devic’s disease: a retrospective study of 33 cases. Neurology 2005;64:A328
59. Mandler RN, Ahmed W, Dencoff JE. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51:1219–1220
60. Falcini F, Trapani S, Ricci L, et al. Sustained improvement of a girl affected with Devic’s disease over 2 years of mycophenolate mofetil treatment. Rheumatology (Oxford) 2006;45:913–915
61. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006;63:957–963
62. Bakker J, Metz L. Devic’s neuromyelitis optica treated withintravenous gamma globulin (IVIG). Can J Neurol Sci 2004;31:265–267
63. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270–1272